Study on the Effect of Dietary Supplements on Height Improvement in Children

NCT ID: NCT05747560

Last Updated: 2023-03-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-06-20

Study Completion Date

2023-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With the increasing improvement of living standard, more and more people are concerned about the body height of their children. It has been reported that 542 out of 1000 children (54.2%) failed to meet the standards of height. Moreover, nearly 80% was disappointed with the height of their children. The body height of child is mainly influenced by 60% of genetic factors (6 out of 10) and 40% of acquired factors which includes nutrition, exercise, sleep, psychology, disease and so on. Therefore, it is an important way to solve the problem by regulating the acquired factors. At present, inject growth hormone (GH) for children is the main way to solve the problem of children's body weight. However, high price, complex operation skills, and side effects limits the implication of GH. Additionally, the effect of traditional Chinese medicine therapy, exercise therapy, and dietary supplement are of dubious benefit and without clinical support. Elevated insulin like growth factor-1 (IGF-1) levels in the human body have been recognized as one of the core criteria for evaluating body enhancement therapy. Currently, there is no dietary supplement intervention to enhance the sensitivity of GH receptor and IGF-1 receptor. The goal of this clinical trial is to test the effect of dietary supplements on height improvement in children (aged 8-15 years of both genders). The main question it aims to answer is: Study the effect of dietary supplements (a formula based on enhancing the sensitivity of GH receptor and IGF-1 receptor) on height improvement in children by.

Participants will be randomly divided into three groups: Placebo, Astragalus extract, and Wolfiporia extract.

1. Participants in the Placebo will consume placebo (a look-alike substances that contains no active drug) at a dose of 500 mg, twice a day (morning and evening) for 6 months. Participants in the Astragalus extract will take dietary supplement with astragalus extract at a dose of 450 mg, twice a day for the same duration. Participants in the Wolfiporia extract will take dietary supplement with wolfiporia extract at a dose of 15 g, twice a day for the same duration.
2. Taken blood sample at the timepoint of baseline (Day 0), intermediate point (Day 90), intervention end point (Day 180)) to detect biochemical markers, as well as body height and weight, and skeletal age.
3. Throughout the trial, subjects were asked to keep their usual lifestyle, food, and physical exercise and not took any dietary supplements.

Researchers will compare the effects of Placebo with Astragalus extract, placebo with Wolfiporia extract, and Astragalus extract with Wolfiporia extract to see if Astragalus extract and Wolfiporia extract increase children's height, and whether Astragalus extract or Wolfiporia extract is more works well.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Body Height Child, Only

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Participants in the Placebo will consume buckwheat at a dose of 500 mg, twice a day (morning and evening) for 6 months.

Group Type PLACEBO_COMPARATOR

Buckwheat

Intervention Type DIETARY_SUPPLEMENT

Take buckwheat at a dose of 500 mg twice a day for 6 months.

Astragalus extract

Participants in the Astragalus extract will take dietary supplement with astragalus extract at a dose of 450 mg, twice a day for the same duration.

Group Type ACTIVE_COMPARATOR

Astragalus extract

Intervention Type DIETARY_SUPPLEMENT

Take astragalus extract at a dose of 450 mg twice a day for 6 months.

Wolfiporia extract

Participants in the Wolfiporia extract will take dietary supplement with wolfiporia extract at a dose of 15 g, twice a day for the same duration.

Group Type EXPERIMENTAL

Wolfiporia extract

Intervention Type DIETARY_SUPPLEMENT

Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Buckwheat

Take buckwheat at a dose of 500 mg twice a day for 6 months.

Intervention Type DIETARY_SUPPLEMENT

Astragalus extract

Take astragalus extract at a dose of 450 mg twice a day for 6 months.

Intervention Type DIETARY_SUPPLEMENT

Wolfiporia extract

Take wolfiporia extract product at a dose of 15 g twice a day for 6 months.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Body height: from the 10th to the 75th;
2. Skeletal age: bone age and actual age ±1.

Exclusion Criteria

1. Treated with growth hormone;
2. Sexual precocity;
3. Abnormal liver and kidney function;
4. IGF levels: below -2SD and above +2SD;
5. IGF BP3 level: below -2SD;
6. Growth hormone deficiency;
7. Diagnosed genetic disease;
8. BMI: Underweight or obese;
9. Abnormal thyroid function.
Minimum Eligible Age

8 Years

Maximum Eligible Age

15 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zhejiang University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Fengqin Feng

Professor Feng

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Fengqin Feng

Role: STUDY_CHAIR

Zhejiang University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

College of Biosystems Engineering and Food Science

Hangzhou, Zhejiang, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Fengqin Feng, Dr

Role: CONTACT

+8613906504026

Qianqian Wang

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Fengqin Feng

Role: primary

13906504026

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Feng8898

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.